Infinity Pharmaceuticals Inc. Pulls Plug on Cancer Drug Saridegib Trials

Published: Jun 19, 2012

Infinity Pharmaceuticals Inc. is stopping its Phase 2 trials of its experimental drug, saridegib, to treat bone and cartilage cancers, saying results have been disappointing. The drug developer said its analysis of the use of saridegib by patients with chrondrosarcoma, a rare and life-threatening cancer of the cartilage, found that results were similar to a placebo. Infinity also said it will discontinue its Phase 2 trial of saridegib in patients with myelofibrosis, an incurable malignancy of the bone marrow, based on data from the cohort of 12 patients that could be evaluated.

Back to news